Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Late Diagnosis: Cause of Poorer Survival in Alcohol-Related Liver Cancer?

April 23, 2018
By Anne Landry
Article

Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis.

Investigators of a large French prospective study published online first in Cancer have suggested that later diagnosis may account for findings of significantly poorer overall survival (OS) in patients with liver cancer caused by alcohol consumption, compared with those whose liver cancer is due to other causes.

Worldwide, liver cancer is the second leading cause of cancer-related deaths, accounting for more than 600,000 deaths annually, according to the American Cancer Society (ACS). The ACS has estimated that, in the United States in 2018, approximately 42,220 new cases of primary liver cancer and intrahepatic bile duct cancer (30,610 in men) will be diagnosed, with about 30,200 cancer-related deaths (20,540 in men). Since 1980, the incidence of liver cancer has more than tripled; and since 2000, liver cancer death rates have increased by almost 3% each year.

With improved treatment of hepatitis B and C virus infections, which are the major risk factors for liver cancer, alcohol consumption is expected to emerge as a leading cause of liver cancer globally. In the United States, the estimated rate of alcohol use disorders is about 30%.

In their study to compare clinical outcomes in patients with alcohol-related vs non–alcohol-related liver cancer, Charlotte Costentin, MD, of Hôpital Henri-Mondor in Créteil, France, and colleagues examined 894 patients with newly diagnosed liver cancer who were followed for 5 years. Sixty-five percent (n = 582) had a history of chronic alcohol abuse and 35% (n = 312) did not. Costentin et al documented whether or not patients with alcohol-related liver cancer were abstinent at the time they were diagnosed with cancer.

At the end of the 5-year study period, 601 patients had died. “Alcohol‐related HCC [hepatocellular carcinoma] was more likely to be diffuse and detected in patients with a worse performance status and worse liver function,” the researchers wrote. Median OS was 9.7 months in patients with non–alcohol-related liver cancer compared with 5.7 months in patients whose liver cancer was alcohol-related (P = .0002). However, median OS was similar in the alcohol‐abstinent (5.8 months) and alcohol nonabstinent groups (5.0 months; P = .09).

Importantly, the investigators reported that “[t]he prognostic role of alcohol disappeared when survival was assessed at each Barcelona Clinic Liver Cancer (BCLC) stage. Patients with HCC detected during a cirrhosis follow‐up program (n = 199 [22.3% of the whole cohort]) had increased lead time–adjusted median OS in comparison with patients with HCC diagnosed incidentally (11.7 vs 5.4 months; P < .0001).”

The results suggest that patients with alcohol-related liver cancer have poorer OS than patients with non–alcohol-related liver cancer mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis, “as attested by similar survival within each BCLC stage,” the researchers wrote.

In light of these findings, Costentin and colleagues have called for improvements in screening programs for cirrhosis and liver cancer, as well as improved patient access to alcoholism treatment services. The hope is that such measures might result in greater numbers of patients with alcohol-related liver cancer who have greater liver function and smaller tumor burdens than were observed in the current study-that is, a clinical condition that would make them better candidates for curative treatment.

 

Recent Videos
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
Related Content
Advertisement

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Roman Fabbricatore
August 5th 2025
Article

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Tim Cortese
August 5th 2025
Article

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.


Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 4th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Related Content
Advertisement

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Roman Fabbricatore
August 5th 2025
Article

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Tim Cortese
August 5th 2025
Article

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.


Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.


More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.


Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC

Roman Fabbricatore
August 4th 2025
Article

Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.